Folgen
Mario de la Fuente Revenga
Mario de la Fuente Revenga
VCU Health
Bestätigte E-Mail-Adresse bei vcuhealth.org
Titel
Zitiert von
Zitiert von
Jahr
Synaptopathies: synaptic dysfunction in neurological disorders–A review from students to students
K Lepeta, MV Lourenco, BC Schweitzer, PV Martino Adami, P Banerjee, ...
Journal of neurochemistry 138 (6), 785-805, 2016
3142016
Deep eutectic solvents (DESs) are viable cosolvents for enzyme-catalyzed epoxide hydrolysis
D Lindberg, M de la Fuente Revenga, M Widersten
Journal of biotechnology 147 (3-4), 169-171, 2010
2902010
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
E Domínguez-Clavé, J Soler, M Elices, JC Pascual, E Álvarez, ...
Brain research bulletin 126, 89-101, 2016
2682016
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
KPC Kuypers, J Riba, M de la Fuente Revenga, S Barker, EL Theunissen, ...
Psychopharmacology 233, 3395-3403, 2016
1842016
The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro
JA Morales-García, M De la Fuente Revenga, S Alonso-Gil, ...
Scientific reports 7 (1), 5309, 2017
1722017
Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
F Sampedro, M de la Fuente Revenga, M Valle, N Roberto, ...
International Journal of Neuropsychopharmacology 20 (9), 698-711, 2017
1672017
Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice
M de la Fuente Revenga, B Zhu, CA Guevara, LB Naler, JM Saunders, ...
Cell reports 37 (3), 2021
1232021
Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
D Ibi, M de la Fuente Revenga, N Kezunovic, C Muguruza, JM Saunders, ...
Nature neuroscience 20 (9), 1247-1259, 2017
882017
Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic …
M de la Fuente Revenga, N Fernandez-Saez, C Herrera-Arozamena, ...
Journal of Medicinal Chemistry 58 (12), 4998-5014, 2015
452015
Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo
M de la Fuente Revenga, JM Shin, HZ Vohra, KS Hideshima, M Schneck, ...
Scientific reports 9 (1), 14247, 2019
442019
Cell-type-specific brain methylomes profiled via ultralow-input microfluidics
S Ma, M de la Fuente Revenga, Z Sun, C Sun, TW Murphy, H Xie, ...
Nature biomedical engineering 2 (3), 183-194, 2018
392018
Temperature and pH Dependence of Enzyme-Catalyzed Hydrolysis of trans-Methylstyrene Oxide. A Unifying Kinetic Model for Observed Hysteresis, Cooperativity …
D Lindberg, M de la Fuente Revenga, M Widersten
Biochemistry 49 (10), 2297-2304, 2010
392010
Recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases
C Herrera-Arozamena, O Martí-Marí, M Estrada, M De la Fuente Revenga, ...
Molecules 21 (9), 1165, 2016
382016
Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: New dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease
A Samadi, M de la Fuente Revenga, C Pérez, I Iriepa, I Moraleda, ...
European journal of medicinal chemistry 67, 64-74, 2013
382013
Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity
M de la Fuente Revenga, D Ibi, T Cuddy, R Toneatti, M Kurita, MK Ijaz, ...
Neuropsychopharmacology 44 (2), 443-454, 2019
362019
HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice
M de la Fuente Revenga, D Ibi, JM Saunders, T Cuddy, MK Ijaz, ...
Neuroscience 388, 102-117, 2018
332018
Differences in 5-HT2A and mGlu2 receptor expression levels and repressive epigenetic modifications at the 5-HT2A promoter region in the Roman low-(RLA-I) and high-(RHA-I …
L Fomsgaard, JL Moreno, M de la Fuente Revenga, T Brudek, ...
Molecular neurobiology 55, 1998-2012, 2018
322018
Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1, 2, 3, 4-tetrahydro-β-carboline (Pinoline) and Melatonin–Pinoline Hybrids
M de la Fuente Revenga, C Perez, JA Morales-Garcia, S Alonso-Gil, ...
ACS Chemical Neuroscience 6 (5), 800-810, 2015
312015
The melatonin analog IQM316 may induce adult hippocampal neurogenesis and preserve recognition memories in mice
J Figueiro-Silva, D Antequera, C Pascual, M de la Fuente Revenga, ...
Cell Transplantation 27 (3), 423-437, 2018
272018
Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
M de la Fuente Revenga, AM Jaster, J McGinn, G Silva, S Saha, ...
ACS chemical neuroscience 13 (16), 2436-2448, 2022
262022
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20